Clinical Research Directory
Browse clinical research sites, groups, and studies.
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ANX005 in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)
Sponsor: Annexon, Inc.
Summary
This study will evaluate the safety and tolerability of ANX005 in participants with Warm Autoimmune Hemolytic Anemia (wAIHA).
Official title: A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Intravenous ANX005 in Subjects With Warm Autoimmune Hemolytic Anemia (wAIHA)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
7
Start Date
2021-11-10
Completion Date
2023-01-17
Last Updated
2026-06-30
Healthy Volunteers
No
Conditions
Interventions
ANX005
ANX005 is provided as a solution for IV infusion
Locations (4)
Investigational Site 01
Rochester, Minnesota, United States
Investigational Site 03
Melbourne, Australia
Investigational Site 04
Vienna, Austria
Investigational Site 02
Sofia, Bulgaria